Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16630480 | 0.87 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL16630526 | 0.84 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL16630528 | 0.82 | PIK3CD (0.42) | HTTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19862015 | 0.81 | PIK3CD (0.56) | HTTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16663361 | 0.80 | PIK3CD (0.45) | HTTPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL11901139 | 0.74 | HTT (0.41) | HTTKDM4EMAPTATMALDH1A1 | |
| SCHEMBL16629027 | 0.73 | PIK3R2 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL18056720 | 0.72 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL30418978 | 0.72 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL21179277 | 0.72 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CGPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 823/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HTT 823/4885PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.